The Lancet General Medicine

Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →